Clinical Trial

Study and Modeling of Perforator Flap Vascularization

Study acronym: EMoVaLP
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2026 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of reconstructive surgery is to restore physical integrity altered by trauma, congenital malformations or cancerous pathologies. Several techniques are available, including flap surgery, which enables tissue to be moved from one anatomical location to another. Perforating skin/subcutaneous flaps are segments of skin and subcutaneous cellular tissue vascularized by a feeder vascular pedicle. This surgical technique has virtually zero donor-site morbidity, as it is no longer necessary to harvest muscle to ensure reliable vascularization of the flap. Flap vascularization is a variable mechanism, complex to describe and understand. For cutaneous and subcutaneous (fatty) flaps, which account for the majority of flaps used, perforator flaps (vascularized by a subcutaneous perforator artery) have become the benchmark. Unfortunately, their vascularization is currently poorly understood, and depends on experimental work carried out on fresh cadaveric anatomical specimens. These cadaveric studies fail to take into account several key factors influencing perforasomes (perforasome: skin territory vascularized by a pedicle), namely body temperature, blood pressure, heart rate, intraoperative patient position and biological parameters.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-17.
Status change: Not Yet Recruiting → Recruiting 2026-04-07
Trial Details
NCT Number NCT07084740
Lead Sponsor University Hospital, Montpellier
Conditions Reconstructive Surgery Using Pedicled Perforating or Free Perforating Flaps, Pelvic Eschar, Traumatic Pathology of the Lower and/or Upper Limb
Enrollment 20 participants
Start Date 2026-02-15
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-13